- €797.12m
- €743.62m
- €19.52m
French and Benelux stocks-Factors to watch
Brief: Medincell FY Revenue EUR 25.4 MLN
Brief: Medincell Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
Bureau Veritas to replace Vivendi on CAC40 index, Euronext says
French and Benelux stocks-Factors to watch
Brief: Medincell H1 Operating Profit Up At EUR -7.5 Mln
Brief: Medincell, AIC Unveil New Positive Phase 3 Results For Mdc-CWM
Brief: Medincell Raises 2024 Uzedy Revenue Outlook To $100 Million
Brief: Medincell's Partner Teva Presents Data From Phase 3 Of Olanzapine Lai
Brief: Medincell-Teva Updates On Pivotal Clinical Phase 3 Of Investigational Olanzapine LAI
Brief: Medincell Announces Product Portfolio And R&D Pipeline Progress
Europe Research Roundup: Admiral, UCB SA, Victrex
Brief: H.C. Wainwright & Co. Initiates Medincell's Coverage With "Buy"
Brief: Medincell FY Operating Loss At EUR 21 Mln
Brief: Medincell Provides Update On Phase 3 Mdc-Cwm Clinical Trial
Teva Pharm Q1 profit misses estimates, revenue risea (updated)
Teva Pharma rises as schizophrenia drug meets main goal of late-stage study
Teva and Medincell's schizophrenia drug meets main goal of late-stage study (updated)
Teva and Medincell's schizophrenia drug meets main goal of late-stage study